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The unique hypervariability of the immunoglobulin (Ig) superfamily provides a means to create
both binding and catalytic antibodies with almost any desired speciﬁcity and activity. The diversity
of antigens and concept of adaptive response suggest that it is possible to ﬁnd an antigen pair to any
raised Ig. In the current review we discuss combinatorial approaches, which makes it possible to
obtain an antibody with predeﬁned properties, followed by 3D structure-based rational design to
enhance or dramatically change its characteristics. A similar strategy, but applied to the second
partner of the antibody–antigen pair, may result in selection of complementary substrates to the
chosen Ig. Finally, 2D screening may be performed solving the ‘‘Chicken and Egg’’ problem when nei-
ther antibody nor antigen is known.
 2012 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Since the early 1970s, when IgG Fab and light chain dimer
structures became available [1,2], it became obvious that detailed
studies of antibody combining sites can provide extremely useful
data concerning antibody–antigen interactions, thereby providing
new insights for biomedical research and for diagnostic and thera-
peutic medicine. Moreover, it has become clear that knowledge of
an exact antibody structure can enable the application of the un-
ique property of efﬁcient in vivo binding in arresting numerous
pathological processes developing within an organism. These
observations have uncovered the enormous therapeutic potential
antibodies that has resulted in an exponential growth of anti-
body-based drugs [3]. On the other hand, the identiﬁcation of nat-
ural antibodies speciﬁc for various targets in biological ﬂuids now
plays an important role as a biomarker of disease and variety of
abnormalities [4].
Initially, antibody generation by scientists was based on the
hybridoma technique [5]. This required researchers to use aalf of the Federation of European B
u.A. Ovchinnikov Institute of
95) 7273860.somewhat unnatural system of adoptive response in living organ-
isms. This approach was like a wormhole: it swallowed up the anti-
gen and afterwards yielded a set of B cells, producing antibodies
towards it. Indeed, the hybridoma technique is now one of the
most important tools in modern immunology and biotechnology,
although it has several signiﬁcant restrictions. Today, dramatic
breakthroughs in immunology, molecular biology, and crystallog-
raphy have made it possible to create antibodies with new, prede-
ﬁned combining sites and rationally designed functionality.
Selection of antibody repertoires from biological ﬂuids, both by
single-cell RT-PCR and phage-display libraries, has extraordinary
potential for diagnostics, therapeutic, and biotechnology purposes.
Moreover, not only antibodies but also antigens can be a target for
combinatorial selection. The broad application of chemical syn-
thetic libraries in the early 1980s, powered by combinatorial biol-
ogy approaches, namely phage display [6,7], has enabled the use of
2D screening of chemical versus Ig libraries.
Immunization by low molecular weight haptens, that mimicked
the transition state of chemical reactions, and by antibodies to-
wards active sites of enzymes, the internal image approach, led
to new artiﬁcial biocatalysts, christened abzymes [8–10]. Since
then hundreds of different chemical transformations have been
shown to be catalysed by abzymes [11,12]. The unique hypervari-
ability of antibody structure offers the possibility to create aOpen access under CC BY-NC-ND license. iochemical Societies.
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may be accomplished by means of the above-mentioned screening
technologies combined with rational design. As reported in our re-
cent study, the screening of phage-display libraries using activated
phosphonate anchors may be considered as a source of novel bio-
catalysts, or ‘‘reactibodies’’ [13].
Different classes of antibody-mediated reactions have been
identiﬁed in autoimmunity [4,14–16]. Using natural mechanisms
of antibody generation it is possible to force the immune system
to produce a catalytic Ig with the required activity. Finally, regard-
less of the origin and selection procedure, each antibody can be
subjected to rational tuning in order to enhance its properties or
develop novel functionality. This review addresses the existing bal-
ance between rational design and high-throughout screening tech-
nologies to probe both antibody and antigen.
2. Combinatorial selection and directed evolution of antibodies.
Reactibodies
Antibodies have a number of unique properties including
good half-life in the blood stream, high speciﬁcity, developed
protocols of expression, as well as a longstanding and successful
application for the treatment of a variety of human diseases. The
idea to bring even several catalytic turnovers to any adopted
therapeutic antibody ‘‘binder’’ may be commercially acceptable
[17]. Current progress in obtaining catalytic antibodies with
various speciﬁcities gives us an exciting opportunity to make
‘‘catalytic vaccines’’ towards toxic low molecular weight mole-
cules such as narcotics, pesticides, and drugs as well as against
bacterial and viral proteins. As an impressive example, it is pos-
sible to mention the cocaine-hydrolysing antibody 15A10, which
in contrast to simply binding Ig [18] signiﬁcantly decreased mor-
tality from cocaine and completely blocked its psycho-active
effect in vivo.
More than 200000 people die annually as a result of poisoning
by organophosphorus (OP) pesticides according to theWHO. More-
over, existing chemical warfare agents are also mainly OPs. In or-
der to ﬁnd an abzyme towards OP compounds in our recent
approach, we have used a combinatorial selection strategy to select
biocatalysts from a human semi-synthetic antibody variable frag-
ment library towards a reactive phosphonate. Phage display is a
selection system whereby genetic information is directly linked
to functional properties (such as enzyme or abzyme activity) of
the coded polypeptide product. A number of such systems has
been described recently [19,20]; some of them have been used in
the selection of efﬁcient catalytic antibodies [21]. Directed selec-
tion of a biocatalyst towards a certain reactive bait was demon-
strated in a report [22]. Such in vitro selection technologies are
extremely useful in the case of antigens potentially toxic for host
animals and therefore not useable for immunization.
With this approach, we selected a diversiﬁed repertoire of hu-
man immunoglobulin variable light (VL) and heavy (VH) single
chain fragments (scFv) displayed on phage particles [22] towards
a biotinylated phosphonate ester. We identiﬁed a set of nucleo-
phile-bearing scFv sites predisposed for covalent catalysis. Se-
quence analysis of the reactive clones revealed preferred pairing
of lambda VL and VH chains with conserved CDR-H3 sequences.
Basically, we observed two main structural motifs employing dis-
tinct tyrosine residues in VL as a nucleophile. The majority of the
clones (7/8) had a tyrosine (Y-L33) residue located in the CDR1
as a putative nucleophile. Nonetheless, A.17, the most reactive
clone, used the tyrosine residue Y-L37 in a conserved framework
also for this purpose. We suggested the term ‘‘reactibody’’ for these
clones to emphasize that they were selected for a chemical reactiv-
ity rather than for ground state binding.Further variable fragments of the A17 reactibody were inte-
grated into the full-length human recombinant antibody and sub-
sequently expressed in CHO cells. The resulted catalytic Ig
demonstrated catalytic activity towards the original aryl phos-
phate ester, comparable to the activity of natural serine hydrolases,
and also a weak esterase activity. High resolution crystallographic
studies of phosphonylated and unmodiﬁed Fabs display a novel,
15 Å-deep, two-chamber cavity between VH and VL chains with
nucleophilic Tyr37L at the base of the site [13]. Detailed examina-
tion of this crystal structure demonstrated that the Tyr37L residue
of the active site can form hydrogen bonds with the N105 and the
carbonyl oxygen atom of the main chain D106 located in the 3rd
hypervariable region of the heavy chain. Thus, aspartic acid 106
and asparagine 105 of the heavy chain may be involved in ‘‘cova-
lent catalysis’’. Further, we substituted two possible nucleophilic
residues identiﬁed in scFv reactibodies Y-L33 and Y-L37 by phen-
ylalanine. In line with previous studies and crystallographic data,
only Y-L37F mutation led to loss of reactivity. Based on pre-steady
state kinetic and X-ray data, we suggested that covalent modiﬁca-
tion of reactibody A.17 by the phosphonate could be described by
an induced-ﬁt model. The nucleophilic efﬁciency of A17 towards
the phosphonate was more than an order of magnitude greater
than the corresponding butyrylcholinesterase (BChE) activity and
compared favourably with typical rates of serine protease covalent
modiﬁcation by phosphonates [23–25]. Importantly, this applied
combinatorial selection towards a reactive phosphonate resulted
in complementary matching of shape and chemical reactivity of
the substrate to the selected reactibody, which exceeded the per-
formance of an enzyme such as BChE with a classical phosphory-
lating agent. To test the ability of A17 to serve as a bioscavenger,
we checked the reactivity for A17 of a number of toxic substances.
Finally, we succeeded in demonstrating that the organophosphate
pesticide paraoxon was hydrolysed by covalent catalysis with rate-
limiting dephosphorylation. We observed accumulation of a cova-
lent intermediate during interaction between A.17 and paraoxon,
which supported the covalent catalysis mechanism for paraoxon
hydrolysis by the A.17 reactibody. Thus, we may state that reacti-
body A17 is therefore a combinatorial-kinetically selected Ig tem-
plate that has enzyme-like catalytic attributes.
Reactive selection demonstrates how architectures that support
efﬁcient chemistry can arise from relatively minor alterations of
the protein interior. Collectively, our observations provide a com-
pelling case of a symbiotic link between the dynamics of the cham-
ber and the reactivity of the tyrosine side chain. Reactibodies have
cavities that facilitate simple chemical processes and provide a
useful model for how these templates may respond to various
adaptations. Strategies to consider antibodies as enzymes have
been criticized on the basis that the Ig template has not the ability
to deploy residues suitable for covalent catalysis and that it lacks
the ﬂexibility required for dynamic mechanism [4]. Reactive
immunization and kinetic selection have provided evidence to dis-
pel these concerns.
Reactibodies thus described may be used as pre-matured tem-
plates to improve existing properties and/or bring novel functional
activities (Fig. 1). The ﬁrst step in rational design is the analysis of
structural data from different sources (X-ray, NMR analysis), ki-
netic studies (both of steady- and pre-steady state kinetics), and
thermodynamic data (ITC, DSC, etc.). All these data together sug-
gest how the reaction is progressing in time and space and what
may be improved rationally in order to enhance it. Precise analysis
of high-resolution X-ray structures can deﬁne distinct amino acid
residues or small clusters as candidates for rational mutagenesis.
High-resolution 3D structures of the reactibody and its phospho-
nylated intermediated have validated this expectation [13]. Several
examples of site-directed mutagenesis of antigen-binding site of
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Fig. 1. Schematic representation of structure- andmechanism-based combinatorial design of reactibodies with enhanced reactivity and novel functions. Amino acids residues
representing the architecture of the active site are deﬁned by various approaches including but not limited to functional and kinetic studies, ITC and X-ray data. The further in
silica 2D screening of libraries of potential substrates versus virtual libraries of selected amino acids residues is performed by combination of QM/MM and MD approaches.
Perspective reactibody mutants are created by site-directed mutagenesis and further subjected to functional analysis towards respective substrate. Resulted reactibody
possesses for enhanced reactivity and novel functions.
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considered.
However, searching for single ‘‘hits’’ is a challenging task because
antibodies, as well as enzymes, combine multiple features to attain
full binding and catalytic activity. Taken individually, these effects
can be almost too small to be identiﬁed. In natural conditions this
problem is overcome by afﬁnity maturation under the pressure of
evolution. The practical realisation of afﬁnity maturation in vitro
by stochastic mutagenesis (error-prone PCR, mutator bacterial
strains [30], saturation mutagenesis [31,32]) is very difﬁcult. Rajpal
et al. developed a rapid and facile method called Look-Through
Mutagenesis (LTM) to provide a comprehensive optimization map
of the antibody-binding site in case of an anti-TNF antibody [33].
They applied an analogue of alanine screen to look over the amino
residues in the CDRof the Ig. Theywere thus able to place the 20nat-
ural amino acids into nine groups and selected one amino acid from
each as a representative member based on chemical structure,
shape, and charge. They then performed a series of single positional
mutations within the CDR where each ‘‘wild type’’ residue was sys-
tematically substituted by one of nine selected amino acids. Finally,
the mutated CDRs were used to construct an scFv combinatorial li-
brary. After positive selection, clones with improved binding were
sequenced and mapped. As a ﬁnal step, combinatorial libraries
(combinatorial beneﬁcialmutations, CBMs) employing all permuta-
tions were produced by mixed DNA probes of positively selected
clones and then further analysed to identify beneﬁcial combinations
of mutations. Rajpal states that afﬁnity of the best-selected scFv to-
wards TNFa was increased up to 870-fold compared to the initial
template, which corresponds to a 30-fold improvement in TNFa
neutralization in vitro, according to L929 bioassay.The development of innovative methods of computational anal-
ysis has made it possible to model molecular mechanisms of the
protein–ligand interactions and identify the second step of biocat-
alyst for optimization (Fig. 1). The molecular docking (MD) tech-
nique allows (i) deﬁnition of the ensemble of amino acids
responsible for ligand binding and (ii) speciﬁcation of types of
molecular interaction critical for the reaction process. Residues
thus identiﬁed are potential targets for site-directed mutagenesis.
This methodology was successfully used by Chang-Guo Zhan’s
group in the redesign of butyrylcholinesterase for anti-cocaine
medication [34]. Assuming that the ﬁrst reaction step (TS1) is rate
limiting, the authors simulated TS1 and demonstrated that the
oxyanion hole of the BChE quadruple mutant A199S/S287G/
A328W/Y332G had stronger binding to the cocaine molecule,
which translates to a reduction of the energy barrier for the ﬁrst
stage of reaction. This mutant had a 456-fold increase in catalytic
efﬁciency for cocaine hydrolysis compared to WT BChE. Another
study on the virtual screening of transition states for cocaine
hydrolysis by BChE used the hybrid quantum mechanical/molecu-
lar mechanics (QM/MM) approach [35]. Combined QM/MM and
MD calculations gave the proﬁle of the whole reaction, while the
MD simulation can be used preferably for modelling of binding
processes or the ﬁrst stage of catalytic reaction. Using this method-
ology, Jorgensen and Alexandrova rationalized the 30-fold reduc-
tion in activity of the E50D variant of catalytic antibody 34E4 for
catalysis of the Kemp elimination [36]. Thus, the next step for
improvement of antibody functionality may be afﬁnity maturation
in silico by computational screening of ‘‘virtual libraries’’ based on
knowledge of antibody structure and reaction proﬁle. Even more
attractive is the possibility that variation of substrate may also
A. Belogurov Jr. et al. / FEBS Letters 586 (2012) 2966–2973 2969be involved in such in silico modelling in order to ﬁnd functional-
ities previously unknown or generated during rational design.
3. Autoimmune disorders provide a natural source to raise
antibodies with novel functionality – the route to epitope-
speciﬁc catalytic response
The discovery of naturally existing abzymes provided a novel
interpretation of role of B cells in autoimmune disorders [15].
Observation of the involvement of the ‘‘abzyme machinery’’ both
in health and disease was a starting point to separate the biology
of catalytic antibodies from purely chemical studies of abzymes
as in vitro catalysts [15,37]. Since the early 1980s, several labora-
tories have initiated studies of natural abzymes and their positive
and negative effect in different physiological processes. Nonethe-
less, besides the striking achievements in disease-associated ab-
zyme studies, it is apparent that many basic aspects still remain
enigmatic [38,39]. The list of natural antigens that appear to be
hydrolysed by antibodies is increasing. However, novel members
that may deﬁnitely be tied to the pathology of a disease are still
under critical consideration. ‘‘Antibody-enzymes’’ were shown to
degrade DNA, RNA, carbohydrates, peptides and proteins [40]. Spe-
ciﬁc catalytic B cell responses were observed in autoimmune, im-
mune, and inﬂammatory disorders such as asthma, Hashimoto’s
thyroiditis, autoimmune myocarditis, multiple myeloma, systemic
lupus erythematous (SLE), scleroderma, rheumatoid arthritis, HIV/
AIDS, sepsis and several animal models of autoimmunity
[14,15,37,39,41,42]. On the other hand, the observed existence of
premature catalytic ‘‘defence abzymes’’ [43] together with the dis-
covery of an antibody-mediated oxidative pathway [44] suggest
that antibody-mediated catalysis may be a protective factor in
the ﬁrst line of combat to balance between innate and adaptive
immunity.
Viral proteins, especially HIV-related ones, are potentially inter-
esting targets for abzymes. The human immunodeﬁciency virus
type I (HIV-I) causes the death of thousands of people all over
the world [45]. The amazing ability of HIV-1 to escape antibody-
mediated neutralization is the reason of the absence of an effective
vaccine [46–49]. To date only a few neutralizing antibodies against
HIV-1 have been described. Elaboration of effective vaccines is re-
quired since these neutralizing antibodies are rarely found in the
sera of HIV-1 infected individuals [50–52]. Among different HIV-
related abzyme activities under consideration [53], antibody-med-
iated gp120 proteolysis seems to be the most promising for clinical
purposes [50–52].
Cell infection by HIV is initiated by interaction of a gp120
homotrimer with the CD4 receptor and CCR/CXCR chemokine co-
receptors on the surface of T-lymphocytes, dendritic cells, and
probably some other cell species. It was reported that gp120 was
unable to interact with CD4 after cleavage by trypsin at residue
432 or by protease V8 at residue 269 [54]. However, directed and
speciﬁc proteolysis of gp120 by proteases in vivo is basically
impossible. Nonetheless, they could be efﬁciently substituted by
abzymes. The molecular structure of gp120 consists of ﬁve con-
stant and ﬁve variable regions. Thus, one of the most favourable
targets for an effective, neutralizing antibody may be the viral
envelope spike that comprises gp120.
If we oversimplify the immunization process, it can be regarded
as selection of a required speciﬁc antibody from a combinatorial
set of antibodies that have been raised towards the antigen by
the immune system. Thus, obtaining an antibody with new func-
tionality is restricted to selection of the speciﬁc antigen and elab-
oration of an appropriate immunization scheme. In our study, we
developed three different strategies to raise gp120-speciﬁc anti-
bodies in autoimmune SJL mice as a potential ‘‘catalytic vaccine’’.The strategy involved: (i) reactive immunization by a pepti-
dylphosphonate, corresponding to a structural part of the coat gly-
coprotein, (ii) immunization using fused epitopes of gp120 and an
encephalogenic peptide, itself a part of myelin basic protein, and
(iii) combined vaccination by DNA and the corresponding gp120
fragments incorporated into liposomes.
We previously reported that fusion proteins containing enceph-
alitogenic peptides could induce a targeted catalytic response to-
wards an antigen [55]. Immunization of animals with a set of
designed antigens containing a fragment of the myelin basic pro-
tein fused to different parts of gp120 molecule resulted in the
induction of site-speciﬁc abzymes towards the targeted protein
[55]. In a separate approach, we obtained a peptidylphosphonate,
LAEEEV-phosphonate constructed using an activated phosphonate
‘‘head’’ and a functional peptide component of the gp120 molecule
(residues 265–270). Similarly to the previous approach, this re-
sulted in the production of catalytic gp120-targeted abzymes.
Co-delivery liposome formulations, that contain a combination
of the parent DNA together with its encoded protein, are able to
deliver the beneﬁts of separate DNA and protein vaccines. They
effectively induce both cell-mediated immunity and antibody re-
sponse against pathogens. Liposome particles are rapidly phagocy-
tized by macrophages with subsequent release of the antigen from
endosomes into the cytoplasm of the macrophages. It has been
suggested that entrapped antigen can enter either the Golgi appa-
ratus or the endoplasmic reticulum and thereby be presented by
MHC class II or class I molecules [56]. Following this idea, we
immunized SJL/J mice by liposome-entrapped gp120 DNA and
the polypeptides encoded by this DNA. Importantly, such com-
bined DNA/protein immunization resulted in titres of gp120-
speciﬁc serum antibodies two orders of magnitude higher than
immunization with gp120 protein alone.
In summary we may state that development of an epitope-
speciﬁc, catalytic response towards the antigen may be effectively
performed against the background of autoimmune abnormalities.
The combination of antibody speciﬁcity and protease activity could
theoretically deliver catalysts targeted at the speciﬁc protein
epitope.
4. Solving the ‘‘Chicken and Egg’’ problem for
immunodiagnostics and treatment by two-dimension
combinatorial screening
At the present time it is evident that B cells can play a signiﬁ-
cant role in autoimmune diseases [4,57]. Their pathological input
includes production of autoantibodies, development of immune
complexes [58], and cytokine and chemokine secretion [59–61].
Conversely, autoantibodies can be used as markers of the develop-
ment [62,63] and progression [62] of autoimmune diseases.
Several of our studies have been related to B cell responses in
patients with multiple sclerosis (MS) which we consider important
both for diagnostics and for treatment of MS. Nowadays, magnetic
resonance imaging (MRI) is an important and widely used method-
ology to verify MS diagnosis. However, the development of a novel
laboratory test will be valuable for clinicians [64]. Unfortunately,
the direct use of antibodies towards myelin basic protein (MBP)
and myelin oligodendrocyte glycoprotein (MOG) for MS diagnostic
in ELISA resulted in controversial results [65,66].
We have demonstrated that autoantibodies from MS patients
towards MBP, one of the major myelin antigens, have a unique
ability not only to bind but also to cleave their antigen [67]. In or-
der to improve MS diagnostics, we further investigated the epi-
tope-speciﬁc activity of these abzymes by examination of the
entire MBP molecule for autoantibody binding and cleavage sites.
As unspeciﬁc binding to the MBP molecule is generally caused by
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tope library’’ of MBP consisting of fragments fused with carrier
protein [70]. Further, we performed ‘‘rational 2D-screening’’ be-
tween a library of 12 MBP fragments and a diversity of serum Ig
from MS patients.
Basically we reported two methodologies for detecting anti-
myelin antibodies based on binding and catalysis. The levels of
autoantibodies towards MBP fragments 48–70 and 85–170 as well
as whole MBP and MOGmolecules were signiﬁcantly higher in sera
of MS patients compared to healthy donors. In contrast, autoanti-
bodies from patients with other neurological disorders (OND)
and MS patients revealed statistically signiﬁcant differences in
binding only to the two MBP fragments 43–68 and 146–170 [70].
Previously mentioned data reporting the controversial linkage of
anti-myelin autoantibodies and MS development are in keeping
with our observations that the binding activities of antibodies to
intact MBP and MOG proteins are indistinguishable for patients
with MS and OND. We suggest that assays based on these frag-
ments may be applied in differential diagnostics of MS and as an
improved prognosis tool for patients with clinically isolated syn-
drome. Analysis of proteolytic activity of autoantibodies towards
an MBP epitope library revealed that patients with MS (77% of pro-
gressive- and 85% of relapsing-remitting) were positive for cataly-
sis while only 9% of patients with OND and no healthy donors were
positive. This demonstrates pronounced epitope speciﬁcity for the
encephalogenic MBP peptide 81–103. This peptide retains its sub-
strate properties when ﬂanked by two ﬂuorescent proteins, provid-
ing a novel FRET approach for MS studies. Our ﬁndings indicate
that site-speciﬁc, abzyme-mediated cleavage of deﬁned MBP pep-
tides may represent a novel diagnostic for MS providing an addi-
tional biomarker of disease progression and may be regarded asFig. 2. Combinatorial screening for novel biomarkers and antibodies towards self-antige
phage-display libraries representing variable fragments of Igs. Further selection of scFv
Resulted full-size human Igs carrying selected variable fragments are tested for crossrea
diseased persons are subjected to differential screening using rationally designed autoant
targets for screening of phage-display Ig libraries and in studies of crossreactivity of alra speciﬁc characteristic of MS compared to healthy donors and
especially OND patients [70].
Following these and other studies, as in the case of T cells [71],
autoreactive B cells can be considered an important target for im-
mune intervention. Unfortunately, existing drugs have massive
side effects and generally are non-speciﬁc. For example, Rituximab
treatment has been reported to cause serious side effects such as
cardiac arrest, tumour lysis syndrome, acute renal failure, hepatitis
B reactivation and other viral infections, progressive multifocal
leukoencephalopathy (PML), immune toxicity with depletion of B
cells from 70% to 80% in lymphoma patients, and pulmonary toxic-
ity [72,73]. Moreover, recent ﬁndings indicate that distinct B cell
subsets may also have essential regulatory functions of suppres-
sion and thus should not be depleted [74–76]. Knowledge about
the speciﬁcity of autoantibodies permits us to suggest the possible
speciﬁcity of respective B cell receptors. With this in mind, the idea
of selective elimination of distinct autoreactive B cells appears very
impressive. Elimination of pathogenic B cells by different immuno-
toxins has been reported previously [77–79]. Basically, these mol-
ecules consist of two parts: an effector domain (toxin, antibody
fragment, RNAse) and a delivery domain (part or full length auto-
antigen). The targeting motif of immunotoxins may selectively
interact with pathogenic B cells via their B cell receptor (BCR)
and cause cell death due to an attached or internalized toxin.
Nonetheless, effective therapies based on the depletion of dis-
ease-associated B cells in autoimmune patients are still lacking.
To elaborate this approach, we designed a panel of genetically
engineered B cell killers that should speciﬁcally interact with one
kind of cells carrying a respective B cell receptor [80]. Immunotox-
ins based on barnase and constant fragment of Ig were able selec-
tively to deplete targeted B cells and decrease production ofns in autoimmune disorders. Lymphocytes from patients are used for obtaining of
towards the autoantigen is followed by their sequencing and functional analysis.
ctivity towards number of autoantigens. Alternatively, serum Igs from healthy and
igen libraries and peptoids libraries. Positive ‘‘hits’’ are subsequently used as a novel
eady selected autoantibodies.
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peutic potential as B cell killing agents. The Fc molecule has addi-
tional beneﬁcial properties due to its high stability in the blood
stream and minimal potential immune response. This approach
using selected agents may further be efﬁciently used for design
of various medications for the directed treatments of autoimmune
diseases via selective depletion of the aggressive pathogenic B cells
in vivo.
Analysis of myelin neuroantigen-speciﬁc antibody repertoires
and their possible cross-reactivity against environmental antigens,
including viral proteins, might shed light on the mechanism of MS
induction and progression. Recently, several reports have de-
scribed MS-associated antibodies detected in blood or cerebrospi-
nal ﬂuid (CSF) of patients [70,81]. The presence of antibodies
against myelin proteins, e.g. myelin oligodendrocyte glycoprotein,
have been reported in a number of studies [82]. Furthermore,
axon-directed antibody responses were deduced from the analysis
of recombinant scFv created by single-cell PCR from individual CSF
B cells [83]. However, several other studies failed to identify any
potential antigens for monoclonal antibodies in MS [84]. Yet other
authors have been able to demonstrate MBP reactivity of clonally
expanded B cells in CSF using recombinant Fab fragments [85].
We have succeeded in demonstrating the epitope-speciﬁcity of
natural anti-MBP Abs [62]. However, analysis of polyclonal Abs de-
nies an understanding of the distinct structures associated with
such speciﬁcities. To address this problem we proposed a two-step
scheme based ﬁrstly on screening of Ig repertoires of MS patients
presented on phage particles and, secondly, reconstruction of arti-
ﬁcial, full size human antibodies and their analysis [86] (Fig. 2). We
hypothesized that this approach could deliver direct structural evi-
dence of the humoral response, which could be relevant to the eti-
ology of MS. Structural alignment of 13 clones selected towards
MBP revealed high homology within their variable regions with
MS-associated CSF antibodies as well as with antibodies towards
latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV)
[87]. One scFv selected on MBP and incorporated into a full-size
human Ig was shown to cross-react with Epstein-Barr latent mem-
brane protein 1 in vitro, suggesting the possible involvement of this
virus in the formation of the pathogenic Ig network. All selected
antibodies were subjected to the rational 2D screening using
MBP epitope library in order to determine their speciﬁcity. Our
ﬁndings suggest a novel ‘‘molecular signature’’ of the EBV in the
humoral MS-associated response, a possible molecular link
between EBV and MS supporting the environmental hypothesis.
During systemic EBV infection, similar autoantibodies may be
raised initially against LMP1 protein and further react with myelin
basic protein in inﬂamed areas, thus triggering an autoimmune
pathology. These observations directly support the hypothesis of
molecular mimicry in the mechanism of MS pathogenesis. The de-
tailed understanding of EBV involvement in MS may have direct
application for the treatment of the disease. For example, suppres-
sion of EBV infectivity by antiviral therapy may decrease the risk of
MS in genetically predisposed individuals and show effectiveness
in some cases of relapsing-remitting MS [88].
These proposed approaches may be signiﬁcantly enhanced by
2D-screening, as recently realized in a study by Reddy et al.
[89].While screening of serum Ig against a priori deﬁned autoanti-
gens may restrict possible candidates, usage of library of thousands
of chemically synthesized peptoids does not require prior knowl-
edge of antigens. Peptiods mimic the ‘‘shape’’ of the antigen rather
its sequence, thus, the distinct antigen will likely remain enig-
matic. These authors investigated two murine models in order to
prove their concept and succeeded in determining possible peptoid
candidates for diagnosis of Alzheimer’s disease. This approach
elaborated in combination with previously mentioned techniquesseems to be a very good prospect for development of novel
diagnostic assays (Fig. 2).
5. Perspectives
Combinatorial screening is a powerful methodology giving un-
ique possibilities for the use of natural or semi-artiﬁcial systems
to select from an initial huge diversity and then focus on either a
distinct antibody or an antigen. The sophisticated screening of nat-
ural repertoires of antibodies towards libraries of autoantigens has
diagnostic and therapeutic potential. The determination of respec-
tive pathogenic B-/T-cell receptors is the ﬁrst step en route to per-
sonalized treatment of autoimmune diseases, making possible the
elimination of pathological cell clones. This kind of therapy may
potentially replace the approach of total B cell depletion, as in
the case of Rituximab, an approved drug with wide a spectrum of
side effects.
By the use of natural mechanisms of antibody generation, it is
possible to force the immune system, against the background of
the autoimmune process, to yield a catalytic Ig having a required
epitope-speciﬁc activity. Thus, the autoimmune repertoire in hu-
mans and model animals may be regarded as a strategic reservoir
for abzyme ‘‘ﬁshing’’. Catalytic antibodies are combining the hith-
erto opposing properties of static immunoglobulins and dynamic
enzymes. They may potentially enhance therapy by clinically ap-
proved ‘‘antibody-binders’’ as a result of adding catalyst turnover
to Ig molecule: ‘‘Catalytic Vaccines’’.
The ‘‘reactibody approach’’, based on screening phage-display li-
braries by reactive chemical compounds,may be regarded as an efﬁ-
cient strategy to obtain artiﬁcial biocatalysts de novo. The extraction
of CDRs with desired functionality using described screening strat-
egies might be followed by the construction of artiﬁcial monoclonal
antibodies inmammalian cells. The Igs produced can be regarded as
a template for further rational design based on 3D structural analy-
sis. The virtual screening of mutants with novel/improved function-
ality can be realized by a combination of molecular dynamics
method and the hybrid quantum mechanics/molecular mechanics
approach. The ﬁrst technique can deliver total interaction energy,
while the second allows calculation of the reaction proﬁle and the
energy barrier. The coherent application of screening technologies,
used both for Ig and substrate libraries, together with rational de-
sign powered by MD and QM/MM calculations using supercomput-
ers like ‘‘Lomonosov’’ with capacity more than 1 petaﬂop s1 may
lead to elaboration of novel ‘‘catalytic vaccines’’.
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